GSK3β and cyclin D1 expression predicts outcome in early breast cancer patients

[1]  G. Freedman,et al.  Impact of Screening and Risk Factors for Local Recurrence and Survival After Conservative Surgery and Radiotherapy for Early Breast Cancer: Results From a Large Series With Long-Term Follow-Up , 2013 .

[2]  J. Mackey,et al.  Clinical and biological significance of GSK-3β inactivation in breast cancer-an immunohistochemical study. , 2010, Human pathology.

[3]  Hiroyuki Takahashi,et al.  Involvement of inactive GSK3beta overexpression in tumorigenesis and progression of gastric carcinomas. , 2010, Human pathology.

[4]  Y. Kuwahara,et al.  Acquired radioresistance of human tumor cells by DNA-PK/AKT/GSK3β-mediated cyclin D1 overexpression , 2010, Oncogene.

[5]  John M S Bartlett,et al.  Histological grading of invasive breast carcinoma – a simplification of existing methods in a large conservation series with long‐term follow‐up , 2009, Histopathology.

[6]  Jia Luo,et al.  Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. , 2009, Cancer letters.

[7]  M. Ellis,et al.  Recommendations for collection and handling of specimens from group breast cancer clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Y. Takano,et al.  Phosphorylated GSK3beta-ser9 and EGFR are good prognostic factors for lung carcinomas. , 2007, Anticancer research.

[9]  John M.S. Bartlett,et al.  Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor–Positive Tumors of Tamoxifen-Treated Breast Cancer Patients , 2007, Clinical Cancer Research.

[10]  A. Thompson,et al.  Cyclin D1 and breast cancer. , 2006, Breast.

[11]  T. Kirkegaard,et al.  Observer variation in immunohistochemical analysis of protein expression, time for a change? , 2006, Histopathology.

[12]  Robin L. Jones,et al.  Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis , 2006, Modern Pathology.

[13]  S. Vranić,et al.  Immunohistochemical evaluation of cyclin D1 in breast cancer. , 2005, Croatian medical journal.

[14]  H. Clevers,et al.  WNT signalling and haematopoiesis: a WNT–WNT situation , 2005, Nature Reviews Immunology.

[15]  I. Ellis,et al.  Best Practice No 176 , 2004, Journal of Clinical Pathology.

[16]  Xi He,et al.  A Wnt-Wnt situation. , 2003, Developmental cell.

[17]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[18]  S. Yanagisawa,et al.  Expression of cyclin D1 and GSK-3beta and their predictive value of prognosis in squamous cell carcinomas of the tongue. , 2002, Oral oncology.

[19]  J. R. Reeves,et al.  Evaluating HER2 amplification and overexpression in breast cancer , 2001, The Journal of pathology.

[20]  G. Cooper,et al.  Role of Glycogen Synthase Kinase-3 in the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway* , 1998, The Journal of Biological Chemistry.

[21]  T. Oyama,et al.  Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. , 1998, Cancer research.

[22]  P. Cohen,et al.  PDK1, one of the missing links in insulin signal transduction? 1 , 1997, FEBS letters.

[23]  G. Peters,et al.  Cyclin D1 and prognosis in human breast cancer , 1996, International journal of cancer.

[24]  Philip R. Cohen,et al.  Multisite phosphorylation of glycogen synthase. Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5). , 1984, Biochimica et biophysica acta.

[25]  P. Cohen,et al.  Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. , 1980, European journal of biochemistry.